North America is expected to dominate the global prophylactic human vaccine market due to the growing focus of key players to launch novel vaccines for treating sexually transmitted diseases in the region. For instance, in August 2020, Dutch firm Intravacc, engaged in translational research and development of viral and bacterial vaccines, has partnered with the US-based Therapyx to further develop and optimize the prophylactic vaccine against gonorrhea, NGoXIM. Therapyx received a $ 2.8 million Phase IIB grant in the US and has chosen to partner with Intravacc for its unique capabilities and infrastructure for the optimization of vaccines, vaccine processes, and vaccine technologies.
The growing prevalence of cervical cancer is primarily fueling the growth of the prophylactic human vaccine market. According to the World Health Organization, Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide and about 311 000 women died from the disease. Moreover, growing health awareness coupled with the advancement in the development of vaccine technology is also expected to augment the growth of the prophylactic human vaccine market. Growing government initiatives for R&D of vaccines and increasing demand for personalized vaccines are again anticipated to propel the growth of the market. For instance, in October 2019, Kenya government introduced the human papillomavirus (HPV) vaccine into the country’s routine immunization programme
Human immunodeficiency virus (HIV) is one of the most common diseases that is affecting people today. This particular virus, if left unchecked can lead to various fatal ailments and life-threatening conditions. There are many types of HIV vaccines available in the market, which includes Bacterial Vaginosis, MVA, and Lymphoma vaccines. These vaccinations help to strengthen the body's natural ability to fight against the infection. Prophylactic Human Vaccine is another effective way of fighting against HIV/AIDS. In this particular form of treatment, pregnant women are given medications to induce their bodies to produce more antibodies to fight against the virus.
The key players operating in the prophylactic human vaccine market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.
No comments:
Post a Comment